trial
as of 2026-07-01Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia
NCTId NCT00894842
at a glance
Phase 2, Phase 3 · Completed
Enrollment 120 (actual)
Sponsored by National Research Foundation, Singapore
Primary completion 2011-09
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2, Phase 3
Status
Completed
Enrollment
120 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-06
Primary completion
2011-09
Eligibility
ALL · 21 Years · 65 Years
Interventions & indications
Drugs
Indications
Sponsors
National Research Foundation, SingaporeLead Sponsor
Duke UniversityCollaborator
National University of SingaporeCollaborator
Singapore Clinical Research InstituteCollaborator
Investigators
1
Siow Ann ChongPrincipal Investigator
Sites
1 total
Singapore, Singapore
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
120
Phase
PHASE2,PHASE3
Primary Completion Date
2011-09
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
company
indication
indication
indication
investigator
person